Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A delphi survey of oncology pharmacists

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2379-2386

  Chan, Alexandre ^a,b   Tan, Seow Hwei ^a   Wong, Chen May ^c   Yap, Kevin Yi Lwern ^a   Ko, Yu ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

Delphi survey; drug safety; drug drug interactions; oral anticancer agents

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BUSULFAN; CAPECITABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; MERCAPTOPURINE; METHOTREXATE; MEZLOCILLIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PENICILLIN V; PHENYTOIN; PIPERACILLIN; PROTEINASE INHIBITOR; RAPAMYCIN; SULFONAMIDE; TICARCILLIN; UNINDEXED DRUG; VORICONAZOLE; VORINOSTAT; WARFARIN;

ARTICLE; AWARENESS; BREAST CANCER; CLINICAL PHARMACOLOGY; COMORBIDITY; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DELPHI STUDY; DIGESTIVE SYSTEM CANCER; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; EVALUATION RESEARCH; HUMAN; MEDICAL EXPERT; MORBIDITY; MORTALITY; NEOPLASM; ONCOLOGY; PANEL STUDY; PHARMACIST ATTITUDE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EID: 84983726617     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.008     Document Type: Article

References (29)

1. Aisner J. Overview of the changing paradigm in cancer treatment: Oral chemotherapy. Am J Health Syst Pharm. 64 Suppl 5 (2007) S4-S7
2. Borner M., Scheithauer W., Twelves C., et al. Answering patients' needs: Oral alternatives to intravenous therapy. Oncologist 6 Suppl 4 (2001) 12-16
3. Blower P., de Wit R., Goodin S., and Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized?. Crit Rev Oncol Hematol. 55 (2005) 117-142
4. Yancik R., and Ries L.A. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 14 (2000) 17-23
5. Karas Jr. S. The potential for drug interactions. Ann Emerg Med. 10 (1981) 627-630
6. Fulda T.R., Valuck R.J., Zanden J.V., et al. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res. 61 (2000) 540-548
7. Abarca J., Malone D.C., Armstrong E.P., et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 44 (2004) 136-141
8. Vitry A.I. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol. 63 (2007) 709-714
9. Wong C.M., Ko Y., and Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: Profiling and comparison of two drug compendia. Ann Pharmacother. 42 (2008) 1737-1748
10. In: Tatro D.S. (Ed). Drug Interaction Facts (2008), Wolters Kluwer, St. Louis, Mo
11. Micromedex Healthcare Series [intranet database]. Version 5.1. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.
12. Skulmoski G.J., Hartman F.T., and Krahn J. The Delphi method for graduate research. J Inform Tech Educ. 6 (2007) 1-20
13. Hajjar E.R., Hanlon J.T., Artz M.B., et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother 1 (2003) 82-89
14. Handler S.M., Hanlon J.T., Perera S., et al. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J Am Geriatr Soc. 56 (2008) 808-815
15. Lindblad C.I., Hanlon J.T., Gross C.R., et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 28 (2006) 1133-1143
16. Malone D.C., Abarca J., Hansten P.D., et al. Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc (2003) 44 (2004) 142-151
17. In: Tatro D.S. (Ed). Drug Interaction Facts (2009), Wolters Kluwer, St. Louis, Mo
18. Clauson K.A., Polen H.H., and Marsh W.A. Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy 27 (2007) 1651-1658
19. Clauson K.A., Marsh W.A., Polen H.H., et al. Clinical decision support tools: Analysis of online drug information databases. BMC Med Inform Decis Mak. 7 (2007) 7
20. Dean R., Nachman J., and Lorenzana A.N. Possible methotrexate-mezlocillin interaction. Am J Pediatr Hematol Oncol. 14 (1992) 88-89
21. Ferrazzini G., Klein J., Sulh H., et al. Interaction between trimethoprim- sulfamethoxazole and methotrexate in children with leukemia. J Pediatr. 117 (1990) 823-826
22. Tracy T.S., Krohn K., Jones D.R., et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 42 (1992) 121-125
23. Rapamune (sirolimus) [package insert] Oral solution and tablets (2005), Wyeth Pharmaceuticals, Inc, Philadelphia, Pa
24. Leather H.L. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: What every transplanter needs to know. Bone Marrow Transplant 33 (2004) 137-152
25. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxali- platin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 22 (2004) 2084-2091
26. Goldhirsch A., Colleoni M., Coates A.S., et al., International Breast Cancer Study Group (IBC-SG). Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike?. Ann Oncol. 9 (1998) 489-493
27. Tashima C.K. Cyclophosphamide effect on coumarin anticoagulation. South Med J. 72 (1979) 633-634
28. Xeloda (capecitabine) Tablets [package insert] (2001), Roche Laboratories Inc, Nutley, NJ
29. Riechelmann R.P., Tannock I.F., Wang L., et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 99 (2007) 592-600